Literature DB >> 16454543

Adverse drug reaction-related hospitalisations: a nationwide study in The Netherlands.

Cornelis S van der Hooft1, Miriam C J M Sturkenboom, Kees van Grootheest, Herre J Kingma, Bruno H Ch Stricker.   

Abstract

BACKGROUND: The incidence of adverse drug reaction (ADR)-related hospitalisations has usually been assessed within hospitals. Because of the variability in results and methodology, it is difficult to extrapolate these results to a national level.
OBJECTIVES: To evaluate the incidence and characteristics of ADR-related hospitalisations in The Netherlands in 2001.
METHODS: We conducted a nationwide study of all hospital admissions in 2001. Data were retrieved from a nationwide computer database for hospital discharge records. All acute, non-planned admissions to all Dutch academic and general hospitals in 2001 were included in the study (n = 668 714). From these admissions we selected all hospitalisations that were coded as drug-related, but intended forms of overdose, errors in administration and therapeutic failures were excluded. Hence, we extracted all ADR-related hospitalisations. We compared age, sex and the risk of a fatal outcome between patients admitted with ADRs and patients admitted for other reasons, as well as the most frequent main diagnoses in ADR-related hospitalisations and which drugs most frequently caused the ADRs. In addition, we evaluated to what extent these ADRs were reported to the Netherlands Pharmacovigilance Centre Lareb for spontaneous ADR reporting.
RESULTS: In 2001, 12 249 hospitalisations were coded as ADR related. This was 1.83% of all acute hospital admissions in The Netherlands (95% CI 1.80, 1.86). The proportion increased with age from 0.8% (95% CI 0.75, 0.85) in the <18 years group to 3.2% in the >/=80 years group (95% CI 3.08, 3.32). The most frequent ADR-related diagnoses of hospitalisations were bleeding (n = 1048), non-specified 'unintended effect of drug' (n = 438), hypoglycaemia (n = 375) and fever (n = 347). The drugs most commonly associated with ADR-related hospitalisations were anticoagulants (n = 2185), cytostatics and immunosuppressives (n = 1809) and diuretics (n = 979). Six percent of the ADR-related hospitalisations had a fatal outcome (n = 734). Older age and female gender were associated with ADR-related hospitalisations. Only approximately 1% of the coded ADRs causing hospitalisation were reported to our national centre for spontaneous ADR reporting.
CONCLUSION: The proportion of ADR-related hospitalisations is substantial, especially considering the fact that not all ADRs may be recognised or mentioned in discharge letters. Under-reporting of ADRs that result in hospital admission to our national centre for spontaneous ADR reporting was considerable.

Entities:  

Mesh:

Year:  2006        PMID: 16454543     DOI: 10.2165/00002018-200629020-00006

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  19 in total

1.  Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance Centres.

Authors:  P Pouyanne; F Haramburu; J L Imbs; B Bégaud
Journal:  BMJ       Date:  2000-04-15

2.  Adverse drug reactions as a cause for admissions to a department of internal medicine.

Authors:  Tom Mjörndal; Marit Danell Boman; Staffan Hägg; Martin Bäckström; Bengt-Erik Wiholm; Anders Wahlin; Rune Dahlqvist
Journal:  Pharmacoepidemiol Drug Saf       Date:  2002 Jan-Feb       Impact factor: 2.890

3.  Adverse drug reaction monitoring--cost and benefit considerations. Part I: frequency of adverse drug reactions causing hospital admissions.

Authors:  N Muehlberger; S Schneeweiss; J Hasford
Journal:  Pharmacoepidemiol Drug Saf       Date:  1997-10       Impact factor: 2.890

4.  Adverse drug reactions and drug non-compliance as primary causes of admission to a cardiology department.

Authors:  F Davidsen; T Haghfelt; L F Gram; K Brøsen
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system.

Authors:  A Alvarez-Requejo; A Carvajal; B Bégaud; Y Moride; T Vega; L H Arias
Journal:  Eur J Clin Pharmacol       Date:  1998-08       Impact factor: 2.953

6.  Drug-related hospital admissions.

Authors:  K M Nelson; R L Talbert
Journal:  Pharmacotherapy       Date:  1996 Jul-Aug       Impact factor: 4.705

7.  Adverse drug reactions as cause of hospital admissions: results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA).

Authors:  Graziano Onder; Claudio Pedone; Francesco Landi; Matteo Cesari; Cecilia Della Vedova; Roberto Bernabei; Giovanni Gambassi
Journal:  J Am Geriatr Soc       Date:  2002-12       Impact factor: 5.562

8.  Adverse reactions to prescribed drugs in the elderly: a multicentre investigation.

Authors:  J Williamson; J M Chopin
Journal:  Age Ageing       Date:  1980-05       Impact factor: 10.668

9.  Contribution of adverse drug reactions to hospital admission of older patients.

Authors:  C K Mannesse; F H Derkx; M A de Ridder; A J Man in 't Veld; T J van der Cammen
Journal:  Age Ageing       Date:  2000-01       Impact factor: 10.668

10.  Is age an independent risk factor of adverse drug reactions in hospitalized medical patients?

Authors:  P Carbonin; M Pahor; R Bernabei; A Sgadari
Journal:  J Am Geriatr Soc       Date:  1991-11       Impact factor: 5.562

View more
  74 in total

1.  Pattern mining for extraction of mentions of Adverse Drug Reactions from user comments.

Authors:  Azadeh Nikfarjam; Graciela H Gonzalez
Journal:  AMIA Annu Symp Proc       Date:  2011-10-22

2.  Generic Substitution Issues: Brand-generic Substitution, Generic-generic Substitution, and Generic Substitution of Narrow Therapeutic Index (NTI)/Critical Dose Drugs.

Authors:  Marian Sorin Paveliu; Simona Bengea; Fraga Silvia Paveliu
Journal:  Maedica (Buchar)       Date:  2011-01

Review 3.  The clinical implications of ageing for rational drug therapy.

Authors:  Shaojun Shi; Klaus Mörike; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-01-05       Impact factor: 2.953

4.  Drug-related deaths: an analysis of the Italian spontaneous reporting database.

Authors:  Roberto Leone; Laura Sottosanti; Maria Luisa Iorio; Carmela Santuccio; Anita Conforti; Vilma Sabatini; Ugo Moretti; Mauro Venegoni
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 5.  A systematic review of hospitalization resulting from medicine-related problems in adult patients.

Authors:  Abdullah Al Hamid; Maisoon Ghaleb; Hisham Aljadhey; Zoe Aslanpour
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

6.  Recognition and management of potential drug-drug interactions in patients on internal medicine wards.

Authors:  Priska Vonbach; André Dubied; Jürg H Beer; Stephan Krähenbühl
Journal:  Eur J Clin Pharmacol       Date:  2007-09-06       Impact factor: 2.953

7.  Detection and prevention of prescriptions with excessive doses in electronic prescribing systems.

Authors:  H M Seidling; A Al Barmawi; J Kaltschmidt; T Bertsche; M G Pruszydlo; W E Haefeli
Journal:  Eur J Clin Pharmacol       Date:  2007-09-05       Impact factor: 2.953

8.  The relationship between study characteristics and the prevalence of medication-related hospitalizations: a literature review and novel analysis.

Authors:  Anne J Leendertse; Djurre Visser; Antoine C G Egberts; Patricia M L A van den Bemt
Journal:  Drug Saf       Date:  2010-03-01       Impact factor: 5.606

9.  Rates of spontaneous reports of adverse drug reactions for drugs reported in children: a cross-sectional study with data from the Swedish adverse drug reaction database and the Swedish Prescribed Drug Register.

Authors:  Susanna M Wallerstedt; Gertrud Brunlöf; Anders Sundström
Journal:  Drug Saf       Date:  2011-08-01       Impact factor: 5.606

10.  Characteristics of unplanned hospital admissions due to drug-related problems in cancer patients.

Authors:  Alexandre Chan; Deren Soh; Yu Ko; Yu-Chu Huang; Joen Chiang
Journal:  Support Care Cancer       Date:  2014-02-22       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.